From: Novel insights into MSC-EVs therapy for immune diseases
Diseases
Clinical trial design
Potential mechanism
Refs
Graft-versus-host disease
individual treatment
decrease IL-1β, TNF-α and IFN-γ; increase IL-10 and TGF-β
[60]
Chronic kidney disease
phase II/III, single centre, randomized, placebo-controlled,
increase TGF-β and IL-10, decreaseTNF-α
[67]
